NCT06215651View on ClinicalTrials.gov

Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

March 11, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2027

Conditions

Cadonilimab and Lenvatinib

Interventions

DRUG

Cadonilimab lenvatinib

±TACE/HAIC

Trial Locations (1)

100730

RECRUITING

Hai-Tao Zhao, Beijing

All Listed Sponsors

lead

Peking Union Medical College Hospital

OTHER